Clinical trials: Resectable Undifferentiated Pleomorphic Sarcoma
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrolizumab, radiation therapy and surgery to standard of care treatment…
- Conditions
- Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT07823491
- Testing
- Biospecimen Collection, Computed Tomography, Doxorubicin
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Sarcoma, Alveolar Soft Part Sarcoma
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI) or body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team…
- Conditions
- Sarcoma, Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors
- Trial name
- SINDIR (NCT03989596)
- Testing
- Hypofractionated radiotherapy, Hyperthermia
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Sarcoma, Fibrosarcoma
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT)…
- Conditions
- Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma
- Trial name
- UN-RESARC (NCT03651375)
- Testing
- Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 46 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
This phase II trial studies how well nivolumab with and without ipilimumab and radiation therapy when given before surgery works in treating patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that…
- Conditions
- Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Resectable Dedifferentiated Liposarcoma
- Trial name
- NCT03307616
- Testing
- Ipilimumab, Nivolumab, Radiation Therapy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable).
- Conditions
- Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma
- Trial name
- NCT04420975
- Testing
- Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida